Evogene Ltd. (NASDAQ: EVGN)

Evogene Ltd. develops a pioneering computational chemistry platform that specializes in the generative design of small molecules for the pharmaceutical and agricultural industries. The company uses its ChemPass AI engine to create novel, highly potent small molecules optimized across multiple parameters for drug development and agrochemical applications.

Evogene Ltd. generates revenue primarily through collaborations and licensing agreements with industry partners, under which partners provide experimental development while the company supplies its ChemPass AI platform to identify and optimize product candidates. Revenue streams consist of upfront payments, research and development fees, and royalties from sales of the resulting commercial products.

The company operates through the following segments: Computational unit, Pharmaceutical unit, and Agricultural unit.

• Computational unit: This unit develops and operates the core ChemPass AI platform, which performs hit screening, hit to lead optimization and de novo molecule generation using ultra large chemical spaces of approximately 38,000,000,000 compounds and tools such as PointHit, ActiveSearch and LeadOp GPT to enable multi parameter constraint based design.

• Pharmaceutical unit: This unit advances the development of novel small molecule drug candidates for human health applications, leveraging ChemPass AI to target diseases such as neurodegenerative disorders, cancers and metabolic conditions through collaborations with research groups and biotech firms.

• Agricultural unit: This unit focuses on agrochemical discovery and development via the subsidiary AgPlenus, employing ChemPass AI to identify new modes of action for herbicides, insecticides and fungicides in partnership with global agrochemical companies.

Evogene Ltd. occupies a specialized niche in the small molecule discovery landscape, competing with large agrochemical corporations such as BASF, Bayer, Syngenta, FMC and Corteva, mid size Japanese agrochemical firms, smaller biotech players and academic research groups. Its competitive advantage lies in the ChemPass AI platform’s ability to explore a vast chemical space, optimize multiple physicochemical and biological parameters simultaneously, and generate novel, synthetically accessible molecules, a capability bolstered by collaborations with Google Cloud and a proprietary suite of algorithms.

Evogene Ltd. serves pharmaceutical and agrochemical companies, research institutions and biotech firms. Key collaborators include Bayer AG, Corteva, Unravel Biosciences, Systasy Bioscience GmbH, LMU University Hospital Munich, the Weizmann Institute of Science and Queensland University of Technology.